Home / Health / New Rosacea Cream Outperforms Standard Care
New Rosacea Cream Outperforms Standard Care
20 Mar
Summary
- New cream showed 54% reduction in redness versus 23%.
- Inflammatory lesions decreased by 74% with new cream.
- The biobotanical cream demonstrated no negative side effects.
A recent clinical trial revealed that Crescel's biobotanical Skin Renewal Cream significantly outperformed a standard metronidazole-based treatment for rosacea. The study, conducted over 12 weeks with 60 adult subjects, showed the new cream achieved a 54% reduction in redness, compared to 23% with the standard care.
Furthermore, inflammatory lesions like papules and pustules saw a 74% decrease with the Crescel cream by Week 8, a result not reached by the comparator group. The biobotanical formulation, featuring naturally derived components and a proprietary delivery system, was also found to be exceptionally well-tolerated, with no adverse effects reported by participants.
This innovative cream has also received recognition from the National Rosacea Society and the National Psoriasis Foundation. Its developers highlighted its potential as a new management approach for rosacea, with ongoing evaluations for other skin conditions like psoriasis and eczema.
